Glucagon News and Research

RSS

Chromium-rich fiber supplement keeps you fuller and reduces insulin spikes

A single dose of a chromium-enriched glucomannan-fructo-oligosaccharide fiber complex significantly reduced postprandial insulin and increased fullness in healthy adults, without affecting blood glucose. These findings highlight the potential of this functional fiber blend to support appetite control and metabolic health.

10 Jun 2025

Midlife weight loss may lower your long-term risk of diabetes, study finds

This study shows that midlife weight loss, without medical interventions, reduces chronic disease risk and supports longevity, beyond diabetes benefits.

29 May 2025

Abdominal fat emerges as independent risk factor for psoriasis in women

Researchers have found that central body fat, especially around the abdomen, is more strongly linked to psoriasis risk than total body fat, particularly in women.

27 May 2025

MRI scans reveal why young women face higher risk for eating disorders

Advanced high-field MRI reveals distinct microstructural changes in hypothalamic subregions of young women with anorexia nervosa and obesity. These alterations may underlie increased vulnerability to eating disorders and point toward new neurobiological treatment targets.

26 May 2025

Trump won’t force Medicaid to cover GLP-1S for obesity. A few states are doing it anyway.

When Page Campbell's doctor recommended she try an injectable prescription drug called Wegovy to lose weight before scheduling bariatric surgery, she readily agreed.

21 May 2025

Gut bacteria and genes jointly shape obesity risk, review reveals hidden links

Researchers examined the heritability of body mass index (BMI), highlighting that genetics and the gut microbiome both play major roles in obesity risk. The review emphasizes that maternal microbiome transmission and family environment may help explain “missing heritability” beyond known genetic factors.

20 May 2025

Hyaluronidase-1 emerges as a key regulator of postmeal blood sugar

A recent study published in Life Metabolism has uncovered a surprising new player in the body's ability to regulate blood sugar after eating.

15 May 2025

GLP-1 weight loss drugs leave users low on key nutrients, study finds

This study assessed nutrient intake in adults using GLP-1 receptor agonists (GLP-1RAs) and found widespread deficiencies in essential vitamins and minerals. Despite appetite suppression and weight loss benefits, most participants exceeded fat intake recommendations and failed to meet protein and micronutrient needs.

14 May 2025

Hormone FGF21 reverses fatty liver disease by signaling the brain

A pioneering research study published today in Cell Metabolism details how the hormone FGF21 (fibroblast growth factor 21) can reverse the effects of fatty liver disease in mice. The hormone works primarily by signaling the brain to improve liver function.

13 May 2025

Online obesity clinic achieves clinical trial-level weight loss with lower semaglutide doses

New research being presented at this year's European Congress on Obesity (ECO 2025) has found that patients of an online obesity clinic achieved similar weight loss to that reported in clinical trials – but with less than half the medication.

12 May 2025

Study shows cardiovascular benefits of GLP-1RAs in patients following bariatric surgery

Medications like semaglutide and liraglutide may help to reduce the risk for heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with obesity and diabetes following bariatric surgery who did not achieve sufficient weight loss and diabetes control, according to new research being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain.

12 May 2025

GLP-1 drugs linked to significant BMI reduction in children with severe obesity

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 agonist drugs form part of their treatment, new research being presented at year's European Congress on Obesity (ECO 2025) suggests.

12 May 2025

Tirzepatide outperforms semaglutide for weight loss in people without diabetes

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in adults with obesity but without diabetes. Over 72 weeks, tirzepatide helped more participants reach key weight loss milestones, with manageable side effects and strong metabolic benefits.

12 May 2025

Tirzepatide outperforms semaglutide in weight loss clinical trial

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the injectable drugs.

12 May 2025

GLP-1RAs show added protection against cancer beyond weight reduction

New research being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May) and published in the journal eClinicalMedicine finds that first generation weight-loss medications like liraglutide and exenatide appear to show anti-cancer benefits beyond weight loss.

11 May 2025

GLP-1 receptor agonists improve mood and metabolic health in adults with mental illness

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in adults with severe mental illness, as well as having positive effects on mood, well-being, and quality of life in those both with and without mental illness, according to a systematic review of the available evidence being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May).

11 May 2025

New stem cell model mimics alpha cell behavior in diabetic conditions

Mor than 800 million people worldwide are living with diabetes, according to World Health Organization (WHO) estimates, with numbers steadily increasing.

8 May 2025

Semaglutide clears liver inflammation and cuts fibrosis in MASH patients, trial shows

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic dysfunction-associated steatohepatitis (MASH). The interim results also reveal meaningful weight loss and improved cardiometabolic markers, with a favorable safety profile.

4 May 2025

High fructose diets impair brain function and appetite control, study shows

Review highlights how excessive fructose intake disrupts brain energy balance, appetite regulation, and cognitive function. Processed sources, such as sugary drinks, may overwhelm metabolic pathways and induce neuroinflammation, particularly during adolescence.

30 Apr 2025

What’s behind Gen Z’s skepticism about Ozempic and Wegovy

A U.S. study of over 500 youth aged 14–24 found high awareness but widespread hesitation about using semaglutide for weight loss. Concerns focused on safety, social stigma, and a preference for lifestyle changes like diet and exercise.

24 Apr 2025